Reuters -- The addition of Schering-Plough Corp’s experimental hepatitis C drug boceprevir after four weeks of treatment with standard medicines led to highly encouraging sustained response rates in a mid-stage study.
Reuters -- The addition of Schering-Plough Corp’s experimental hepatitis C drug boceprevir after four weeks of treatment with standard medicines led to highly encouraging sustained response rates in a mid-stage study.
